AOD-9604 — Peptide Protocol Wiki reference

AOD-9604: HGH Fragment for Fat Loss Research | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

AOD-9604 is not approved for human therapeutic use by any regulatory agency worldwide.

Mechanism of Action # Lipolytic Activity # AOD-9604's primary pharmacological effect is the stimulation of lipo

Under FDA review regarding compounding pharmacy regul

Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About AOD-9604 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides AOD-9604 Weight Loss & Metabolism Healing & Tissue Repair discontinued AOD-9604 Also known as: Anti-Obesity Drug 9604, hGH Fragment 176-191, AOD9604, Tyr-hGH(177-191) Research compiled by Peptide Protocol Wiki 📅 Updated February 8, 2026 Citations Verified TL;DR AOD-9604 is a synthetic 16-amino acid peptide derived from the C-terminal region of human growth hormone (residues 176-191) with an N-terminal tyrosine substitution.

s of full-length hGH • Does not affect serum IGF-1 levels or carbohydrate metabolism at studied doses • Extensive human safety database from over 900 participants across six clinical trials • Investigated for cartilage repair and osteoarthritis applications • Does not compete for the hGH receptor or induce cell proliferation Community-Reported Side Effects Anecdotal ?

📋 Protocol Quick-Reference Fat metabolism research and body composition improvement 💉 Dosing Amount 250-300 mcg Frequency Once daily Duration 8-12 weeks 💊 Administration Route SC Schedule Once daily Timing Morning on empty stomach, 30 minutes before first meal ✓ Rotate injection sites 📅 Cycle Duration 8-12 weeks Repeatable Yes Preparation & Storage Diluent: Bacteriostatic water Storage: Store lyophilized AOD-9604 at -20 degrees Celsius in a sealed, desiccated container.

Protect from light and avoid exposure to strong reducing agents that could break the disulfide bond.

Why: Confirm AOD-9604 does not affect GH/IGF-1 axis (it should not) Thyroid panel (TSH, Free T4) When: Baseline Why: Rule out thyroid-related metabolic issues CMP When: Baseline Why: Liver and kidney function baseline Fasting insulin When: Baseline Why: Baseline insulin sensitivity 💡 Key Considerations → Administer on empty stomach in morning for best results → No fasting insulin or glucose changes expected → Contraindication: Avoid in pregnancy or active cancer; failed Phase IIb clinical trial and was abandoned by the pharmaceutical developer Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

AOD-9604 was administered orally and demonstrated no significant adverse effects.

Phase IIa studies : Early efficacy trials showed trends toward weight loss in obese subjects.

Restore access No thanks, continue reading Related Reading Peptide HGH Fragment 176-191 lipolytic growth hormone fragment Peptide HGH 191AA full-length recombinant growth hormone Article AOD-9604, Tesamorelin & MOTS-C Stack Guide How AOD-9604 works at the cellular level Overview of AOD-9604 benefits and applications Scientific Details Molecular Formula C78H123N23O23S2 Molecular Weight 1815.12 Da CAS Number 221231-10-3 Sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe What is AOD-9604?

Regulations vary by country and may change.

The proposed mechanism involves: Beta-3 adrenergic receptor upregulation : Chronic treatment with AOD-9604 increases the expression of beta-3 adrenergic receptors (beta-3 AR) on adipocytes.

While AOD-9604 does not act directly through the beta-3 AR, the increased receptor expression may enhance lipolytic sensitivity to endogenous catecholamines.

Studies in beta-3 AR knockout mice showed that the weight loss effects of AOD-9604 were abolished, confirming the importance of this pathway (PMID: 11713213).

Fat oxidation enhancement : AOD-9604 increases the rate of fat oxidation (the metabolic burning of fatty acids for energy).

This was demonstrated in obese mice, where chronic AOD-9604 treatment significantly increased in vivo fat oxidation rates (PMID: 11673763).

Separation from hGH Effects # A critical feature of AOD-9604's design is the separation of lipolytic activity from other hGH effects: Effect Full-length hGH AOD-9604 Lipolysis Yes Yes Growth promotion Yes No IGF-1 elevation Yes No Hyperglycemia Yes No Cell proliferation Yes No hGH receptor binding Yes No Insulin resistance Yes No This selectivity is possible because the C-terminal domain of hGH (from which AOD-9604 is derived) contains the lipolytic region of the molecule, which operates through a mechanism distinct from

the growth hormone receptor (GHR).

The proposed mechanisms include stimulation of proteoglycan and collagen synthesis in chondrocytes, though this area of research is still in early stages.

published two landmark studies in 2001: PMID: 11673763 : Demonstrated that chronic treatment of obese (ob/ob) mice with AOD-9604 increased fat oxidation and reduced body weight without affecting insulin secretion or glucose homeostasis, establishing the metabolic selectivity of the fragment.

PMID: 11713213 : Showed that AOD-9604's lipolytic effects in obese mice were mediated through beta-3 adrenergic receptor pathways.

In beta-3 AR knockout mice, AOD-9604 failed to produce weight loss, confirming the receptor dependence of the mechanism.

Clinical Trials # AOD-9604 underwent six human clinical trials: Phase I studies : Established safety and tolerability in healthy volunteers.

ts receiving oral AOD-9604 (1 mg/day) lost an average of 2.6 kg compared to 0.8 kg in the placebo group.

In the United States, it is classified as Not FDA-approved for therapeutic use.

Despite trends toward weight loss, the study failed to achieve its primary endpoint of statistically significant weight reduction compared to placebo.

e in metabolic syndrome management Safety profile supporting metabolic applications Novel mechanism distinct from other anti-obesity approaches Safety Profile # The most notable aspect of AOD-9604's clinical history is its extensive safety database.

Key safety findings from clinical trials include: No effect on IGF-1 : Serum IGF-1 levels unchanged during treatment No hyperglycemia : Unlike hGH, AOD-9604 does not impair glucose metabolism No growth effects : No cell proliferation or growth-promoting activity detected Well tolerated : Adverse event rates similar to placebo across clinical trials No hormonal disruption : No significant effects on thyroid, adrenal, or gonadal function Evidence Gaps and Limitations # AOD-9604 failed its primary weight loss endpoint in the largest clinical trial Cartilage repair evidence is primarily preclinical The mechanism of action for cartilage effects is not well characterized Long-term safety data beyond 24 weeks is limited Optimal dosing for cartilage applications has not been established Products available from research chemical suppliers lack pharmaceutical standardization Whether oral bioavailability is sufficient for systemic effects remains debated The relationship between AOD-9604 and full-length hGH in cartilage repair is unclear Key Research Findings # Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone , published in Hormone Research (Ng FM et al., 2000; PMID: 11

146367): The study demonstrated demonstrated that oral AOD-9604 at 500 mcg/kg/day reduced body weight gain by over of 50% in obese Zucker rats over 19 days, with increased lipolytic activity and no adverse effect on insulin sensitivity.

Related Reading # AOD-9604 research studies and evidence AOD-9604 dosing protocols AOD-9604 side effects profile Adipotide research guide CJC-1295 DAC research guide Stay current on AOD-9604 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

What are the benefits of AOD-9604?

following potential benefits of AOD-9604: Stimulates fat metabolism (lipolysis) without the growth-promoting effects of full-length hGH.

Does not affect serum IGF-1 levels or carbohydrate metabolism at studied doses.

Extensive human safety database from over 900 participants across six clinical trials.

Does not compete for the hGH receptor or induce cell proliferation.

What are the side effects of AOD-9604?

Reported side effects of AOD-9604 include injection site reactions.

Most reported side effects are mild and transient.